NYSE: CRL

Charles River Laboratories International (CRL) Stock Analysis & Forecast

Nov 13 close

$337.97−2.84 (−0.8%)

Gekko Brief

AI summaryNov 9 close

Charles River Laboratories moves this week on an acquisition and a guidance update. The company has agreed to acquire Frontage Holdings Corporation's bioanalysis and DMPK businesses for up to $545 million, with reports specifying approximately $470 million in cash plus potential additional payments of up to $75 million, with the operations located in Exton, Pennsylvania. Separately, the company raised its 2026 GAAP EPS guidance to $8.15 to $8.35, a move attributed primarily to a third-quarter tax reserve reversal, alongside what coverage describes as mild top-line pressure.

CRL closes at $353.34, up 4.7%, sitting above both its 50-day average of $306.83 and its 200-day average of $225.23, with the 50-day above the 200-day. The stock's one-month return stands at 17.1% and its one-year return at 106.8%, near its 52-week high of $379.63. The GekkoIndex reads 53.5, placing it in the Neutral zone, while price sits 33.8% above Gekko Fair Value of $264.16.

Looking ahead, the next earnings date falls on 17 February 2027, 94 days away and outside a typical 20-trading-day hold. Over the last 30 days, one unusual options signal appears, with put premium of $1,553,540 against call premium of $432,250. Seasonality from this point in the calendar shows the next 20 trading days averaging a 0.4% return over 5 years, rising in 2 of them. Analyst consensus among 15 firms shows 14 buy and 1 hold ratings, with a consensus target of $318.87.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Charles River Laboratories International price vs fair value

$337.97$277.70Nov ’25May ’26Nov ’26
Close $337.97200-day averageGekko Fair Value $277.70

Charles River Laboratories International quick facts

Market cap
$16.19B
P/E ratio
370.5
Forward P/E
27.8
EPS, TTM
$0.92
Revenue, TTM
$3.98B
Profit margin
1%
Dividend yield
—
Beta
1.34
Volume
807,009 avg 1.29M
1-year return
+97.1%
Typical daily move
±5.5%
Typical 20-day move
±8%
50-day average
$311.06
200-day average
$227.71
Next earnings
Feb 17 before open
Shares outstanding
47.92M
52-week range
$146.20$379.63

Charles River Laboratories International swing-trade checklist

Charles River Laboratories International scores 2 supportive, 2 mixed and 2 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed2 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $337.97 is above the 50-day ($311.06) and 200-day ($227.71) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    56.2, Neutral

    Reading 56.2 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    21.7% above

    Price is 21.7% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyheadwind

    Leans bearish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 94 days

    Next report Feb 17, 2027, 94 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +2.5% on average

    From this point in the calendar, the next 20 trading days averaged +2.5% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Charles River Laboratories International stock chart and price history

Charles River Laboratories International closed at $337.97 on Nov 13, 2026, +97.1% over the past year, inside a 52-week range of $146.20 to $379.63.

Close50-day average200-day averageVolume
Charles River Laboratories International share price, past year, with 50-day and 200-day moving averages and volume$150$200$250$300DecJan 2026FebMarAprMayJunJulAugSepOctNov337.97

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+10.4%
3 months
+17.9%
6 months
+124.0%
1 year
+97.1%
The full CRL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CRL in Gekko

Follow Charles River Laboratories International through every session

Put CRL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track CRL in GekkoFree for 7 days. No credit card required.

About Charles River Laboratories International

Charles River Laboratories International serves pharmaceutical and biotechnology firms by acting as an outside research partner for the early stages of drug development. Clients turn to it for help discovering new compounds, running non-clinical studies, and confirming that candidate drugs are safe before moving forward, and it has built a name for breeding and supplying laboratory rats and mice used in that experimentation.

Its work is split across three business areas. One focuses on producing research-grade rodents, including genetically modified strains, and on services that help laboratories manage animal colonies, outsource facility operations, and run diagnostics on research animals. Another concentrates on the science behind early drug development, helping clients pinpoint and confirm promising targets, molecules, and antibodies, then evaluating them through toxicology work, pathology review, safety pharmacology, bioanalysis, metabolic profiling, and pharmacokinetic analysis. A third handles testing tied to manufacturing, checking the sterility and quality of drugs and consumer goods, performing specialized biologics testing on behalf of client companies, and supplying materials used in vaccine production, such as disease-free eggs and birds along with related diagnostic tools. Beyond these three areas, the company also operates animal housing facilities under contract for biopharmaceutical clients, and its client base spans the United States, Europe, Canada, and Asia Pacific.

Its shares trade on the NYSE under the ticker CRL.

Listed
NYSE
Sector
Commercial services
Industry
Miscellaneous commercial services
Website
criver.com

Charles River Laboratories International GekkoIndex: the smart money zone

Charles River Laboratories International’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56.2, in the Neutral zone, up 0.9 points over five sessions.

010056.2Neutral

Up 0.9 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying45−0.7%+2.2%+3.2%+2.4%
Accumulation245+1.1%+1.3%+3.0%+3.9%
Neutral (current zone)339+0.6%+1.4%+2.0%+4.2%
Distribution66−0.6%−1.2%−1.5%+2.1%
Selling7Too few readings yet

Average CRL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the CRL price, zone by zone.Track CRL in Gekko

Is Charles River Laboratories International stock overvalued? Gekko Fair Value

Charles River Laboratories International trades 21.7% above Gekko Fair Value of $277.70, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Charles River Laboratories International shares are worth, recalculated every trading day.

$277.70

Gekko Fair Value, Nov 14, 2026

21.7% Overvalued

At the end of Aug 2026 the price was 45.1% above the estimate.

Gekko Fair ValueShare price, month end
$278$338Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open CRL in Gekko

Charles River Laboratories International insider and Congress trading

No open-market insider purchases were filed for Charles River Laboratories International, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for CRL in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every CRL insider filing, plotted on the chart in Gekko.Open CRL in Gekko

Congress trades last 90 days

No trades in CRL were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for CRL, plotted on the chart in Gekko.Open CRL in Gekko

Buybacks

Charles River Laboratories International has been buying back its own shares.

Bought back, quarter ended Sep 26, 2026
$224K
As a share of market cap
0.00%
Trailing four quarters
$324.2M

From company filings.

Unusual options activity last 30 days

1signal, 22% of the flagged premium in calls.

Latest: Bearish flow on Nov 3, $1.99M in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

0of the funds Gekko tracks hold CRL.

0added0opened0trimmed2sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Charles River Laboratories International earnings: next date and track record

Charles River Laboratories International reports on Feb 17, 2027, before the open (94 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±9.1%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+11.5%Nov ’24+5.1%Feb ’25+22.5%May ’25−10.6%Aug ’25−3.9%Nov ’25+3.6%Feb ’26−2.3%May ’26+13.4%Aug ’26

Last earnings call, Aug 5, 2026 AI summary

What they said
Charles River Labs beat Q2 2026 targets and raised full-year guidance. DSA net book-to-bill rose to ~1.2x, the third consecutive quarter above 1.0x and highest in nearly 4 years. Total company returned to organic revenue growth at 0.1%, first positive organic growth since Q3 2023. Operating margin improved 420 basis points sequentially to 20.5%, aided by divestitures of European discovery services, CDMO, and Cell Solutions businesses. A new collaboration with Eli Lilly's TuneLab AI platform was announced.
Guidance
Management raised full-year 2026 financial guidance following Q2 outperformance. The company expects accelerating organic revenue growth in H2 2026, supported by strengthening biopharmaceutical demand and a streamlined post-divestiture portfolio.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026$3.02
est $2.74
+10.2%$1.00B
est $977.2M
+2.8%+13.4%
May 7, 2026$2.06
est $1.96
+5.1%$995.8M
est $977.5M
+1.9%−2.3%
Feb 18, 2026$2.39
est $2.35
+1.7%$994.2M
est $987.0M
+0.7%+3.6%
Nov 5, 2025$2.43
est $2.32
+4.7%$1.00B
est $987.2M
+1.8%−3.9%
Aug 6, 2025$3.12
est $2.50
+24.8%$1.03B
est $968.9M
+6.5%−10.6%
May 7, 2025$2.34
est $2.06
+13.6%$984.2M
est $958.8M
+2.6%+22.5%
Feb 19, 2025$2.66
est $2.50
+6.4%$1.00B
est $948.2M
+5.7%+5.1%
Nov 6, 2024$2.59
est $2.42
+7.0%$1.01B
est $976.0M
+3.5%+11.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Charles River Laboratories International stock forecast and analyst price targets

Analysts’ average 12-month price target for Charles River Laboratories International is $346.07, +2.4% from the last close, from 15 firms rating the stock in the last 90 days.

$346.07consensus 12-month target, +2.4% from the last close
Low $315High $400
Buy14
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 15 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 11TD CowenBuy, maintained$388+14.8%
Nov 6Mizuho SecuritiesHold, maintained$315−6.8%
Nov 5BarclaysBuy, maintained$375+11.0%
Nov 5Robert W. BairdBuy, maintained$364+7.7%
Nov 5Bank of America SecuritiesBuy, maintained——
+2.0%average 20-day move after past Neutral readings
+2.5%average move over the next 20 trading days in the last 5 years
±5.5%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Charles River Laboratories International seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Charles River Laboratories International averaged +2.5% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−8.1%2021−13.7%2022+22.2%2023−3.3%2024+18.1%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.9%1 of 5
Next 10 trading days+1.2%2 of 5
Next 15 trading days−0.2%2 of 5
Next 20 trading days+2.5%2 of 5
Next 30 trading days+6.0%2 of 5

For scale, CRL’s typical 20-trading-day move in either direction is about 8%.

Charles River Laboratories International market cap and key statistics

Charles River Laboratories International’s market cap is $16.19B, with a P/E ratio of 370.5 and revenue of $3.98B over the last twelve months.

Valuation

Market cap
$16.19B
P/E ratio
370.5
Forward P/E
27.8
EPS, TTM
$0.92
Gekko Fair Value
$277.70

Trading

Volume
807,009
Avg volume, 20 days
1.29M
52-week high
$379.63
52-week low
$146.20
Shares outstanding
47.92M

Financials

Revenue, TTM
$3.98B
Profit margin
1%
Return on equity
1.3%
Quarterly earnings growth, YoY
+524.0%

Risk and income

Beta
1.34
Typical daily move
±5.5%
Typical 20-day move
±8%

Charles River Laboratories International peers

Charles River Laboratories International’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
SHOPShopify−0.1%Accumulation0.6% above
CTASCintas−0.6%Neutral22.3% above
PYPLPayPal+1.1%Neutral5.3% above
XYZBlock+2.8%Neutral15.1% above
FISVFiserv+3.7%Distribution38.0% below
CPAYCorpay+0.6%Distribution5.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Miscellaneous commercial services

Charles River Laboratories International stock FAQ

What is Charles River Laboratories International’s market cap?

Charles River Laboratories International’s market cap is $16.19B at the Nov 13, 2026 close of $337.97, with 47.92M shares outstanding. The shares trade on a P/E ratio of 370.5.

What is the Charles River Laboratories International stock forecast?

The consensus analyst 12-month price target for Charles River Laboratories International is $346.07, +2.4% from the last close. Of the 15 firms that rated the stock in the last 90 days, 14 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Charles River Laboratories International stock overvalued or undervalued?

On Gekko’s estimate Charles River Laboratories International is overvalued: the Nov 13, 2026 close of $337.97 is 21.7% above Gekko Fair Value of $277.70. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Charles River Laboratories International report earnings next?

Charles River Laboratories International is expected to report on Feb 17, 2027, before the market opens (94 days away). Analysts expect earnings of $3.32 per share on revenue of $970.2M. Charles River Laboratories International beat the earnings estimate in 8 of its last 8 reports, moving 9.1% on average across the report.

What is Charles River Laboratories International’s 52-week high and low?

Charles River Laboratories International’s 52-week high is $379.63 and its 52-week low is $146.20; it closed at $337.97 on Nov 13, 2026, +97.1% over the past year. Over the last five years the shares peaked at $397.77 on Nov 16, 2021.

Is Charles River Laboratories International stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 6 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 2 as headwinds (fair value and smart money). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Charles River Laboratories International?

Gekko flagged 1 unusual options signal in Charles River Laboratories International over the last 30 days, with $432K of flagged premium in calls and $1.55M in puts. The latest, bearish flow, was on Nov 3, 2026 with $1.99M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Charles River Laboratories International the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.